Transcatheter patent ductus arteriosus closure: what have we learned after over 25 years? A single--center experience with 1036 patients.

Background: Transcatheter patent ductus arteriosus (PDA) closure has become the first‑choice method of treatment in the majority of patients. However, device selection poses a challenge.

Aims: This study aimed to analyze periprocedural and 1‑year outcomes of PDA transcatheter closure performed with different devices throughout a 25‑year time period in a single center.

Transcatheter Closure of Patent Ductus Arteriosus in Elderly Patients: Initial and One-Year Follow-Up Results-Do We Have the Proper Device?

Objectives: Patent ductus arteriosus (PDA) in elderly patients is an uncommon anomaly, and the duct itself is often calcified and fragile; therefore, transcatheter closure is more difficult. The aim is to analyse periprocedural and one-year follow-up results of transcatheter closure of PDA in such patients. .

Medium- and long-term follow-up of transcatheter closure of ruptured sinus of Valsalva aneurysm in Central Europe population.

Background: We aimed to evaluate medium- and long-term outcomes of transcatheter closure (TC) of ruptured sinus of Valsalva aneurysm (RSVA), which is a rare and mostly congenital heart disease.

Methods: Retrospective analysis included 23 patients (14 males) aged 15-79 years (y; 39.9±18.

Transcatheter closure of atrial septal defects type 2 in children under three years of age.

Background: Atrial septal defect (ASD) type 2, according to current standards, is closed percutaneously usually after the child has reached the age of four to five years. There are limited data regarding such treatment in younger infants.

Aim: We sought to evaluate the feasibility, safety, and efficacy of percutaneous ASD closure in children under three years of age.

Native aortic coarctation stenting in patients ≥ 46 years old.

Introduction: Stent implantation is an effective therapy for aortic coarctation (CoA) in adolescents and adults.

Aim: To present a unique group of patients with native coarctation of the aorta older than or equal to 46 years treated with bare metal or covered stents.

Material And Methods: Since 2002 we have performed stent implantations by applying bare metal stents or covered stents using femoral access in 24 patients aged 46 and older.

Immediate and long‑term outcomes of native aortic coarctation and postsurgical aortic recoarctation treated with stent implantation: a single‑center experience.

INTRODUCTION    Stent implantation has become the treatment of choice for native aortic coarctation (CoA) and postsurgical aortic recoarctation (reCoA) in adults and adolescents. OBJECTIVES    This study aimed to compare the immediate and long‑term outcomes of patients with native CoA and postsurgical reCoA who underwent stent implantation in our center. PATIENTS AND METHODS    The data of 136 patients with native CoA and reCoA who underwent stent implantation between May 1999 and December 2016 were retrospectively analyzed.

Implantation of stents for postsurgical recoarctation of the aorta in adolescents and adults.

Background: Results of stent implantation (SI) of postsurgical recoarctation of the aorta (ReCoA) are not frequently published.

Aim: This study sought to retrospectively evaluate results of SI in ReCoA in older children and adults.

Methods: Twenty-eight SIs were performed on 26 ReCoA patients with a median age of 23 (10-65) years.

Immediate and long-term outcomes of percutaneous transcatheter pulmonary valve implantation.

Background: Transcutaneous pulmonary valve replacement (TPVR) has become an alternative to heart surgery for patients after previous right ventricular outflow tract (RVOT) or pulmonary artery (PA) surgical interventions. The objective was to present immediate and long-term outcomes of trans¬cutaneous pulmonary valve replacement.

Methods: Between 06/2009 and 06/2016, 46 patients underwent TPVR.

Percutaneous closure of an aortopulmonary window using Amplatzer Duct Occluder II: Additional Sizes: the first reported case.

To date, there are no reported cases of the Amplatzer Duct Occluder II: Additional Sizes' use in percutaneous closure of an aortopulmonary window. We report a case of percutaneous closure of an aortopulmonary window in a 4.5-month-old, 6 kg child.

Are the AMPLATZER Duct Occluder II Additional Sizes devices dedicated only for smaller children?

Aims: The aim of this study was to present our experience with the AMPLATZER Duct Occluder II Additional Sizes (ADOIIAS) for the closure of different types of patent ductus arteriosus (PDA) in patients of various age groups.

Methods And Results: A group of 103 patients, in whom the PDA (diameter below 3.5 mm) was closed using the ADOIIAS, was analysed.